Video Source: www.youtube.com
Sanofi-Aventis (SNY) ADRs are higher on a Bloomberg report that the French drugmaker may be valuing Genzyme (GENZ), which it has been looking to acquire over the past nine months, at about $76 to $77 a share, or $20 billion. The value includes payments connected to sales of an experiment drug to treat multiple sclerosis. Yesterday, Genzyme reportedly said ongoing discussions with Sanofi had progressed to the point where Genzyme's board authorized the company to enter into a confidentiality agreement with SNY in order to allow SNY to conduct due diligence. These discussions have focused to a significant degree on the potential use of a contingent value right for alemtuzumab as a part of a potential resolution of the differences in valuation between the parties, and the parties have also discussed other potential terms for a negotiated transaction. Sanofi ADRs are up 2.85%, or $0.98, to $35.39. Genzyme shares are up 1.1%.